+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating treatments for participants with metastatic colorectal cancer who have a specific KRAS p.G12C mutation and have not received prior treatment. The study compares progression-free survival between two groups one receiving sotorasib, panitumumab, and FOLFIRI, and the other receiving FOLFIRI with or without bevacizumab-awwb. This is a phase 3 randomized trial aiming to understand which combination better manages the disease. Participants in one group take sotorasib daily as an oral tablet while receiving panitumumab and FOLFIRI every two weeks through intravenous infusions. The other group receives FOLFIRI every two weeks, with or without bevacizumab-awwb, also given by intravenous infusion every two weeks. The study treatments continue according to these schedules to compare their effects. Throughout the trial, participants will undergo assessments to measure progression-free survival using RECIST v1.1 criteria for up to approximately three years. Additional outcomes like overall survival, response rates, duration of response, and safety events are monitored for up to five years. Researchers will collect blood samples to measure sotorasib levels during early treatment cycles. Participants are closely observed through scheduled visits and tests to evaluate treatment effects and safety over the study duration.

Age: 18Years +All GendersPhase 3
291 locations
C

Actively Recruiting

Researchers are evaluating the real-life effectiveness and safety of three different treatmentsvedolizumab, ustekinumab, and JAK inhibitorsin patients with ulcerative colitis UC who have previously been treated with at least one anti-TNF-alpha therapy. This observational study aims to compare these therapies over a period of 12 months to better understand how they perform in routine clinical settings. The study includes patients who are starting one of the three treatments as a second-line target therapy after anti-TNF-alpha failure or intolerance. The treatments being observed are vedolizumab, ustekinumab at standard dosage, and JAK inhibitors such as tofacitinib, upadacitinib, or filgotinib. Participants receive their prescribed treatments as part of their usual medical care the study monitors their progress and outcomes without altering treatment. Participants will be followed for at least one visit after starting the treatment to assess clinical and endoscopic effectiveness over 12 months. Researchers will collect data on how well each treatment controls disease activity and safety profiles. The study involves regular clinical assessments according to routine practice to evaluate participants health status and treatment responses during this period.

Age: 18Years +All Genders
1 location